Normal or improved cardiovascular risk factors in IGF-I-deficient adults with growth hormone receptor deficiency.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-07-12 Epub Date: 2024-04-26 DOI:10.1016/j.medj.2024.03.022

Jaime Guevara-Aguirre, Amrendra Mishra, Marco Canepa, Carolina Guevara, Álvaro Villacres, Alexandra Guevara, Gabriela Peña, Daniela Lescano, John J Kopchick, Priya Balasubramanian, Valter D Longo

{"title":"Normal or improved cardiovascular risk factors in IGF-I-deficient adults with growth hormone receptor deficiency.","authors":"Jaime Guevara-Aguirre, Amrendra Mishra, Marco Canepa, Carolina Guevara, Álvaro Villacres, Alexandra Guevara, Gabriela Peña, Daniela Lescano, John J Kopchick, Priya Balasubramanian, Valter D Longo","doi":"10.1016/j.medj.2024.03.022","DOIUrl":null,"url":null,"abstract":"Background: Human subjects with generalized growth hormone (GH) insensitivity due to GH receptor deficiency (GHRD)/Laron syndrome display a very low incidence of insulin resistance, diabetes, and cancer, as well as delayed age-related cognitive decline. However, the risk of cardiovascular disease (CVD) in these subjects is poorly understood. Here, we have assessed cardiovascular function, damage, and risk factors in GHRD subjects and their relatives.Methods: We measured markers of CVD in two phases: one in a cohort of 30 individuals (GHRD = 16, control relatives = 14) brought to USC (in Los Angeles, CA) and one in a cohort including additional individuals examined in Ecuador (where the subjects live) for a total of 44 individuals (GHRD = 21, control relatives = 23). Data were collected on GHRD and control groups living in similar geographical locations and sharing comparable environmental and socio-economic circumstances.Results: Compared to controls, GHRD subjects displayed lower serum glucose, insulin, blood pressure, smaller cardiac dimensions, similar pulse wave velocity, lower carotid artery intima-media thickness, lower creatinine, and a non-significant but major reduction in the portion of subjects with carotid atherosclerotic plaques (7% GHRDs vs. 36%, Controls p = 0.1333) despite elevated low-density lipoprotein cholesterol levels.Conclusion: The current study indicates that individuals with GHRD have normal or improved levels of cardiovascular disease risk factors as compared to their relatives.Funding: This study was funded in part by NIH/NIA grant P01 AG034906 to V.D.L.","PeriodicalId":29964,"journal":{"name":"Med","volume":null,"pages":null},"PeriodicalIF":12.8000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11246805/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2024.03.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Human subjects with generalized growth hormone (GH) insensitivity due to GH receptor deficiency (GHRD)/Laron syndrome display a very low incidence of insulin resistance, diabetes, and cancer, as well as delayed age-related cognitive decline. However, the risk of cardiovascular disease (CVD) in these subjects is poorly understood. Here, we have assessed cardiovascular function, damage, and risk factors in GHRD subjects and their relatives.

Methods: We measured markers of CVD in two phases: one in a cohort of 30 individuals (GHRD = 16, control relatives = 14) brought to USC (in Los Angeles, CA) and one in a cohort including additional individuals examined in Ecuador (where the subjects live) for a total of 44 individuals (GHRD = 21, control relatives = 23). Data were collected on GHRD and control groups living in similar geographical locations and sharing comparable environmental and socio-economic circumstances.

Results: Compared to controls, GHRD subjects displayed lower serum glucose, insulin, blood pressure, smaller cardiac dimensions, similar pulse wave velocity, lower carotid artery intima-media thickness, lower creatinine, and a non-significant but major reduction in the portion of subjects with carotid atherosclerotic plaques (7% GHRDs vs. 36%, Controls p = 0.1333) despite elevated low-density lipoprotein cholesterol levels.

Conclusion: The current study indicates that individuals with GHRD have normal or improved levels of cardiovascular disease risk factors as compared to their relatives.

Funding: This study was funded in part by NIH/NIA grant P01 AG034906 to V.D.L.

查看原文本刊更多论文

生长激素受体缺乏的 IGF-I 缺乏成人的心血管风险因素正常或有所改善。

背景：因生长激素受体缺乏症（GHRD）/拉隆综合征而导致全身生长激素（GH）不敏感的人类受试者中，胰岛素抵抗、糖尿病和癌症的发病率非常低，与年龄相关的认知能力衰退也有所延迟。然而，人们对这些受试者罹患心血管疾病（CVD）的风险却知之甚少。在此，我们对 GHRD 受试者及其亲属的心血管功能、损伤和风险因素进行了评估：我们分两个阶段测量了心血管疾病的标志物：一个阶段是在南加州大学（加利福尼亚州洛杉矶市）对 30 名受试者（GHRD = 16 人，对照组亲属 = 14 人）进行队列测量，另一个阶段是在厄瓜多尔（受试者居住地）对 44 名受试者（GHRD = 21 人，对照组亲属 = 23 人）进行队列测量。收集的数据来自生活在相似地理位置、具有相似环境和社会经济条件的 GHRD 组和对照组：结果：与对照组相比，GHRD 受试者的血清葡萄糖、胰岛素、血压较低，心脏尺寸较小，脉搏波速度相似，颈动脉内膜中层厚度较低，肌酐较低，尽管低密度脂蛋白胆固醇水平升高，但颈动脉粥样硬化斑块的受试者比例明显减少（GHRD 为 7%，对照组为 36%，P=0.1333）：本研究表明，与亲属相比，GHRD 患者的心血管疾病风险因素水平正常或有所改善：本研究部分由美国国立卫生研究院/美国国立卫生研究院授予 V.D.L. 的 P01 AG034906 基金资助。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.